Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and Head of Medical Research at SanBio Group, Published in

  Research Paper Co-authored by Dr. Damien Bates, Chief Medical Officer and
  Head of Medical Research at SanBio Group, Published in Stroke

Business Wire

TOKYO -- May 24, 2018

The SanBio Group (SanBio Co., Ltd. and subsidiary SanBio, Inc.), a scientific
leader in regenerative medicine for neurological disorders, hereby announces
that Cell Therapy for Chronic Stroke, a research paper co-authored by the
group’s Chief Medical Officer and Head of Medical Research, Dr. Damien Bates,
and other researchers, was published in Stroke, a professional journal issued
by American Heart Association. The research paper gives an overview of recent
advances in R&D of therapeutic agents targeting chronic motor deficits and
also reports on development progress and potential of a regenerative medicine
product SB623 being developed by SanBio. The R&D covers therapy and
therapeutic agents in regards to chronic motor deficit from ischemic stroke in
particular, the paper summarizes characteristics, advantages, and proven
efficacy of cell medicines that vary depending on origin of the cell and route
of administration. Further, it reviews progress of clinical trials for the
treatment of chronic motor deficit from ischemic stroke being conducted around
the world.

Upon publishing the paper, Dr. Damien Bates said, “I hope this research will
draw attention to regenerative medicine research for the treatment of chronic
motor deficit from ischemic stroke and significantly progress establishment of
effective therapeutic agents targeting patients with chronic motor deficit
from ischemic stroke in the US and around the world.” Regarding SB623 being
developed by SanBio, he further added, “While clinical trials of SB623 are
progressing smoothly, we wish to further prepare for delivering the medicine
product to the market and respond to the growing unmet medical needs in the US
and around the world.”

In the SB623 development program targeting chronic motor deficit from ischemic
stroke, SanBio is conducting a phase 2b clinical trial based on the results of
the phase 1/2a clinical trial. Enrollment of 163 patients has already been
completed, and results of the trial are scheduled to be released in the first
half of the fiscal year ending January 2020 (February 2019 to July 2019)
following a 12-month follow-up period. Further, SanBio has completed
enrollment of 61 patients for a phase 2 clinical trial in the SB623
development program targeting chronic motor deficit from traumatic brain
injury (TBI). The results of the trial are scheduled to be released in the
fiscal year ending January 2019 (February 2018 to January 2019).

References:
“Update on Development Progress of Regenerative Cell Medicine SB623,” released
on April 2, 2018

SanBio, Inc. and SanBio Co., Ltd.
SanBio group is engaged in the regenerative medicine business spanning
research, development, manufacture, and sales of regenerative medicines. In
regards to its propriety regenerative medicine product SB623, SanBio is
conducting a phase 2b clinical trial for the treatment of chronic motor
deficit from ischemic stroke in the US together with its development partner
in the US and Canada, Sumitomo Dainippon Pharma Co., Ltd. On its own, SanBio
is conducting a global phase 2 clinical trial of SB623 targeting chronic motor
deficit from TBI in Japan and the US. Headquartered in Tokyo, SanBio has its
main R&D base in Mountain View, California in the US.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20180524006523/en/

Contact:

For more information, contact:
SanBio Co., Ltd.
Masahito Kumagae, +81-3-6264-3481
Management Administration
Press spacebar to pause and continue. Press esc to stop.